Wendy J M van de Ven1, J P Michiel Sedelaar2, Marloes M G van der Leest3, Christina A Hulsbergen-van de Kaa4, Jelle O Barentsz3, Jurgen J Fütterer3, Henkjan J Huisman3. 1. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Wendy.vandeVen@radboudumc.nl. 2. Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
OBJECTIVES: To determine transrectal ultrasound (TRUS) visibility of magnetic resonance (MR) lesions. METHODS: Data from 34 patients with 56 MR lesions and prostatectomy were used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to Prostate Imaging-Reporting and Data System (PIRADS) and Gleason scores. RESULTS: TRUS visibility occurred in 43% of all MR lesions and in 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS-visible lesions had a Gleason 4 or 5 component. CONCLUSIONS: Almost half of the MR lesions were visible on TRUS. TRUS-visible lesions were more aggressive than TRUS-invisible lesions.
OBJECTIVES: To determine transrectal ultrasound (TRUS) visibility of magnetic resonance (MR) lesions. METHODS: Data from 34 patients with 56 MR lesions and prostatectomy were used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to Prostate Imaging-Reporting and Data System (PIRADS) and Gleason scores. RESULTS: TRUS visibility occurred in 43% of all MR lesions and in 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS-visible lesions had a Gleason 4 or 5 component. CONCLUSIONS: Almost half of the MR lesions were visible on TRUS. TRUS-visible lesions were more aggressive than TRUS-invisible lesions.
Authors: Susan John; Steven Cooper; Rodney H Breau; Trevor A Flood; Ilias Cagiannos; Luke T Lavallee; Christopher Morash; Joseph O'sullivan; Nicola Schieda Journal: Can Urol Assoc J Date: 2018-06-19 Impact factor: 1.862
Authors: Wulphert Venderink; Marloes van der Leest; Annemarijke van Luijtelaar; Wendy J M van de Ven; Jurgen J Fütterer; J P Michiel Sedelaar; Henkjan J Huisman Journal: World J Urol Date: 2017-09-04 Impact factor: 4.226